6ix — Find Your Next Investment

Discover investor relations events, company profiles, and opportunities on 6ix. Connect with public companies and attend live investor events.

Please enable JavaScript to use all features of 6ix.com.

Oorspronkelijke tekst

Deze vertaling beoordelen

Je feedback wordt gebruikt om Google Translate te verbeteren

Latest Press Releases

Time	Headline
6m ago	Tripadvisor Announces 2026 Travelers' Choice Awards: Best of the Best Things to Do, Recognizing the World's Most Loved Travel Experiences and Attractions
6m ago	DXC Introduces DXC OASIS to Reimagine Managed Services for the AI Era
20m ago	Enduro Metals Announces $5 Million LIFE Offering
20m ago	Adelayde Exploration Commences Work Program on the Sisson North Tungsten Project Directly Bordering Northcliff Resources
20m ago	Emperor Metals Hit Visible Gold Again at Duquesne West Gold Project

About

Protalix Biotherapeutics, Inc. (de) — investor relations, events, news, and company updates on 6ix.

Latest News

Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results

Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) ▼

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU

Community Chat

Ask AI